The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
 
Oliver Klein
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Damien Kee
No Relationships to Disclose
 
Bo Gao
Consulting or Advisory Role - MSD
 
Ben Markman
Travel, Accommodations, Expenses - Akeso Biopharma
 
Linda R. Mileshkin
No Relationships to Disclose
 
Clare L. Scott
Research Funding - Clovis Oncology; Eisai; Roche/Genentech; Sierra Oncology
Patents, Royalties, Other Intellectual Property - Royalty agreement for venetoclax (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca
Other Relationship - Clovis Oncology
 
Yeojeong So
Travel, Accommodations, Expenses - Roche
 
Richelle Linklater
No Relationships to Disclose
 
Andreas Behren
No Relationships to Disclose
 
Jodie Palmer
Stock and Other Ownership Interests - Avecho
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; IDEAYA Biosciences; MSD; Novartis; Pierre Fabre; Roche
 
Jonathan S. Cebon
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Roche (Inst)
Consulting or Advisory Role - Amgen (Inst); Amgen (Inst); Bionomics; Bionomics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst)
Research Funding - CSL Behring (Inst); GlaxoSmithKline (Inst)
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
Expert Testimony - Bristol-Myers Squibb